Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
New trial design could improve early-stage cancer studies involving CAR-T therapies
Researchers have developed a new statistical approach that could help improve how early-stage cancer trials identify the safest and most effective doses of advanced therapies, such as CAR-T therapy.
Researchers develop gene-editing platform to systematically decode histone function in mammalian cells
Scientists have developed a powerful new gene-editing platform that allows them, for the first time, to systematically test the function of key proteins in mammalian cells.
New clinical trial design could improve dose selection, maximising treatment efficacy and safety
Researchers have developed a new approach to help determine the optimal dose of cancer drugs, aiming to make early-stage clinical trials more transparent and better aligned with patient needs.
The ICR and The Royal Marsden partner with Mint Medical on roll out of global AI cancer imaging tool
The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have announced a new licensing agreement with MedTech company Mint Medical, a Snke Company, to improve monitoring for patients with bone disease in advanced prostate cancer and multiple myeloma.